This approach has been therapeutically beneficial for several cancer types with particular genomic alterations, including BCR-ABL kinase inhibition for chronic myeloid leukemia and KIT inhibition for gastrointestinal stromal tumor (GIST), as well as BRAF and Her2 inhibition for multiple tumor types1,2. The gene discussed is ABL1; the disease is gastrointestinal stromal tumor.